Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Master Service Agreement with ChemConnection BV, a Dutch contract manufacturing organization (CMO) to produce and supply clinical-grade MagSense® nanoparticle formulations for the Company’s planned HER2 breast cancer human clinical studies.
View the ASX announcement, “Imagion Biosystems Secures Nanoparticle Manufacturer.”
The Stock Network Interview – Making the business case for MagSense® cancer imaging
Izaac Ronay from The Stock Network sat down with Imagion Biosystems’ Ward Detwiler to discuss the new written series, “10 Things to Know About MagSense®”, which
